Could a heart drug curb alcohol cravings in HIV patients?
NCT ID NCT06004830
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This small pilot study tested whether giving spironolactone, a drug normally used for heart conditions, could help people with HIV reduce their alcohol use. Twenty-one participants received the drug along with support from a pharmacist and psychiatrist. The study focused on whether this approach was practical and safe, and looked for early signs it might cut down drinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- spironolactone
- What this could lead to
- If this works, it could point toward a new way to help people with HIV reduce their drinking.
- What could go wrong
- This is a very small pilot study with only 21 people, no comparison group, and it's testing a drug not approved for this use. Results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlanta VA Medical Center
Decatur, Georgia, 30033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?